ArticleThe Journal of thoracic and cardiovascular surgery2026
Ventricular arrhythmias in patients undergoing degenerative mitral repair: Prevalence and impact on survival.
Article in The Journal of thoracic and cardiovascular surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Arrhythmogenic Mitral Valve Prolapse: Looking Beyond Mitral Regurgitation.JACC. Case reports · 2026Article
- Arrhythmic Mitral Valve Prolapse as a Regional Stretch-Induced Cardiomyopathy with Fibro-Inflammatory Signature: A Conceptual Review.Journal of cardiovascular development and disease · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundVentricular arrhythmias occur in a subset of patients with mitral valve prolapse; however, their impact on postoperative survival after degenerative mitral repair is unclear.
methodsWe compared long-term survival after degenerative mitral repair in patients presenting with and without arrhythmic mitral valve prolapse (defined by degenerative mitral regurgitation and ventricular arrhythmias) in a national insurance database. Our primary outcome was survival up to 5 years; secondary outcomes were implantable cardiac defibrillator (ICD) and ventricular arrhythmia-related readmissions. Multivariable adjustment accounted for baseline differences. Median follow-up was 3.8 years (interquartile range, 1.5-6.6 years).
resultsAmong 20,980 patients, 1745 (8.3%) had arrhythmic mitral valve prolapse, of whom 1121 (64%) underwent surgical repair and 624 (36%) underwent transcatheter edge-to-edge repair (TEER). The 5-year survival after surgical repair was 86% in patients with arrhythmic mitral valve prolapse compared to 81% in patients without (hazard ratio [HR], 0.79; 95% confidence interval [CI], 0.64-0.97; P = .02). The 5-year survival after TEER was 34% in patients with arrhythmic mitral valve prolapse compared to 43% in patients without (HR, 1.26; 95% CI, 1.07-1.49; P < .001). Rates of ICD were higher following surgery in patients with arrhythmia (1.3% vs 0.4%; P < .01) and similar following TEER in the 2 groups (0.6% vs 0.4%; P = .5).
conclusionsArrhythmic mitral valve prolapse is not associated with worse survival after surgical mitral repair; however, arrhythmic mitral valve prolapse is associated with significantly worse survival after TEER. Prospective mechanistic studies are needed to elucidate the pathophysiology of and inform treatment choices in patients with arrhythmic mitral valve prolapse.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.